GLP-1s: A Quiet Drop-Off in Seniors
For many seniors, breakthrough weight-loss drugs deliver real benefits — until insurance denials, side effects, or muscle loss force them to quit.
-
By
-
Paula Span
-
January 6, 2026
-
Clinical Scorecard: GLP-1s: A Quiet Drop-Off in Seniors
At a Glance
| Category | Detail |
|---|
| Condition | Obesity and Type 2 Diabetes in Older Adults |
| Key Mechanisms | GLP-1 receptor agonists promote weight loss and improve glycemic control. |
| Target Population | Adults aged 65 and older, particularly those with obesity and Type 2 diabetes. |
| Care Setting | Primary care and specialty clinics. |
Key Highlights
- Approximately 40% of older adults have obesity, with nearly 30% having Type 2 diabetes.
- 60% of seniors with diabetes discontinue semaglutide within a year.
- Common side effects include gastrointestinal issues such as nausea and diarrhea.
- Muscle loss can occur with GLP-1 use, leading to frailty and increased fall risk.
- Cost and insurance coverage are significant barriers to continued use of GLP-1 medications.
Guideline-Based Recommendations
Diagnosis
- Assess body mass index (BMI) and consider diabetes status in older adults.
Management
- Consider GLP-1 receptor agonists for weight management in eligible patients.
Monitoring & Follow-up
- Regularly monitor weight, blood glucose levels, and side effects.
Risks
- Monitor for gastrointestinal side effects and potential muscle loss.
Patient & Prescribing Data
Older adults, particularly those with obesity and Type 2 diabetes.
Medications may require long-term use for sustained benefits; cost is a major factor in adherence.
Clinical Best Practices
- Encourage exercise and strength training to mitigate muscle loss.
- Educate patients on the necessity of long-term medication adherence.
- Advocate for insurance coverage changes to improve access to GLP-1 medications.
References
